Are GlaxoSmithKline plc And Legal & General Group Plc Great Dividend Picks For 2016 And Beyond?

Is now the perfect time to buy high-yielding GlaxoSmithKline plc (LON:GSK) and Legal & General Group Plc (LON:LGEN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are some cracking dividends on offer at the moment among the elite companies of the FTSE 100.

The index itself currently yields 3.9%, but a number of individual stocks are flaunting considerably higher yields.

Today, I’m looking at whether GlaxoSmithKline (LSE: GSK) at 5.8% and Legal & General (LSE: LGEN) at 5.2% are great dividend picks for 2016 and beyond.

GlaxoSmithKline

GlaxoSmithKline has faced a number of headwinds in recent years, as have its big pharma peers. Constrained public health budgets, expiring patents and competition from generics have hit top- and bottom-line growth. For Glaxo, a bribery scandal in China hasn’t helped, either.

The table below show some key earnings and dividend data for the company.

  2012 2013 2014 2015 forecast 2016 forecast
Earnings per share growth (%) -2 -4 -12 -20 +11
Dividend per share growth (%) +6 +5 +3 0 0
Dividend cover 1.5x 1.4x 1.2x 0.9x 1.1x

As you can see, earnings began to decline at an accelerating rate from 2012, yet management continued to increase the dividend each year, with the result that dividend cover began to drop.

Obviously, a trajectory of falling earnings and rising dividends can’t continue indefinitely, and earlier this year — with earnings forecast to plunge 20% — Glaxo’s management took the decision to hold the 2015 dividend at the same 80p level as 2014. And also intends to hold it at 80p for 2016 and 2017.

As the table shows, earnings won’t quite cover the 2015 dividend. However, the good news is that analyst are expecting Glaxo to return to earnings growth in 2016, with an 11% rise, which reflects guidance from the company itself. Earnings would then be back to covering the dividend, albeit by a slim 1.1x.

Additionally, though, Glaxo has taken steps to help it get through the dip in dividend cover. As well as the ordinary dividend, management had originally intended to pay a special dividend of a further 80p for 2015, out of cash realised from a deal with Novartis. However, the Board has decided to reduce the special to 20p; thus retaining most of the cash from Novartis, effectively making the ordinary dividend more secure through the next couple of years of lean cover.

Obviously, investors can’t expect to see an increase in Glaxo’s dividend until after 2017 — and rises for a few years thereafter are likely to lag earnings growth, until the company has rebuilt dividend cover, probably to around the 1.5x level. However, the current high starting yield of 5.8% (excluding the 20p one-off special dividend) appears good compensation, and now could be a good time to buy a slice of this world-class business.

Legal & General

In contrast to Glaxo, Legal & General has been on a roll in recent years. The insurer and asset manager has been increasing earnings at a good clip, and shareholders have seen tasty annual rises in their dividends.

The table below show some key earnings and dividend data for the company.

  2012 2013 2014 2015 forecast 2016 forecast
Earnings per share growth (%) +11 +10 +10 +14 +7
Dividend per share growth (%) +20 +22 +21 +19 +7
Dividend cover 1.8x 1.6x 1.5x 1.4x 1.4x

As you can see, while Glaxo has been suffering falling earnings, L&G has been knocking out regular double-digit annual growth — and increasing the dividend at twice the rate of earnings.

Management has been keen that shareholders benefit from the recovery since the financial crisis, but we should note that the generous dividend payouts have brought cover down from 1.8x to an expected 1.4x this year. The boom period for dividend growth is over, and L&G is expected to increase payouts in line with earnings growth going forward, maintaining dividend cover at around 1.4x.

L&G is a strong business, and mid-to-high single digit earnings and dividend growth looks sustainable for the foreseeable future. The forecast 2016 dividend gives a yield of 5.2%, which appears highly attractive when combined with the company’s decent growth prospects for the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »